The Full Wiki

More info on Fulvestrant

Fulvestrant: Wikis

  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Fulvestrant
Systematic (IUPAC) name
13-methyl-7-[9-( 4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]- 7,8,9,11,12,13,14,15,16, 17-decahydro- 6H-cyclopenta[a] phenanthrene-3,17-diol
Identifiers
CAS number 129453-61-8
ATC code L02BA03
PubChem 104741
DrugBank APRD00654
Chemical data
Formula C 32H47F5O3S 
Mol. mass 606.772 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 99%
Metabolism  ?
Half life 40 days
Excretion  ?
Therapeutic considerations
Pregnancy cat. D
Legal status Rx only
Routes Intramuscular injection
 Yes check.svgY(what is this?)  (verify)

Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.[1] It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Clinical uses

Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

External links

References

  1. ^ S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36.







Got something to say? Make a comment.
Your name
Your email address
Message